Palisade Bio's Q3 2026 Form 10-Q, filed on November 10, disclosed a Development Funding Agreement and Call Option Agreement with Nexys Therapeutics. Under the agreement, PALI may provide up to $3.5 million toward development expenses and holds an option to acquire Nexys. 🔹 Key Highlights Agreement Date: The agreements were originally executed on September 22, 2026. Development Funding: Palisade Bio may fund up to $3.5 million in development expenses. Acquisition Option: PALI holds a call option to acquire Nexys Therapeutics. NEX003: A preclinical, tissue-specific AhR agonist targeting inflammatory bowel disease (IBD). NEX002: A preclinical, tissue-specific ALK5 inhibitor, also targeting IBD development opportunities. Disclosure: The agreements were detailed in PALI's Q3 2026 10-Q filing. 💡 Why It Matters The agreement gives Palisade Bio access to two additional preclinical IBD assets and a potential acquisition pathway. This could expand its development pipeline, but the assets remain at an early stage. Investors should monitor funding commitments, the terms and exercise conditions of the call option, and further clinical development progress. Source: SEC Filing — Palisade Bio Q3 2026 Form 10-Q 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified